Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | VCP | P55072 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | FBP1 | P09467 | 1/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30577771 | 1.00 | NPC1 (1.00) | NPC1MTORRAB9AVCPCYP3A4 | |
| SCHEMBL16211885 | 1.00 | NPC1 (1.00) | NPC1MTORRAB9AVCPCYP3A4 | |
| SCHEMBL744716 | 1.00 | NPC1 (1.00) | NPC1MTORRAB9AVCPCYP3A4 | |
| Piperonal SCHEMBL6073053 | 0.94 | NPC1 (0.88) | NPC1MTORRAB9AVCPCYP3A4 | |
| Piperonal SCHEMBL6073058 | 0.94 | NPC1 (0.88) | NPC1MTORRAB9AVCPCYP3A4 | |
| SCHEMBL2742581 | 0.90 | VCP (0.82) | NPC1MTORRAB9AVCPMAPT | |
| SCHEMBL4997484 | 0.90 | VCP (0.82) | NPC1MTORRAB9AVCPMAPT | |
| SCHEMBL13799666 | 0.87 | VCP (0.77) | NPC1MTORRAB9AVCPCYP3A4 | |
| SCHEMBL67999 | 0.83 | NPC1 (0.71) | NPC1MTORRAB9AVCPCYP3A4 | |
| SCHEMBL19097687 | 0.81 | PTPN1 (0.71) | NPC1MTORRAB9AVCPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 461 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| EP-4636093-A1 | TARGETING MAPK-ERK PATHWAY FOR ENHANCING NUCLEIC ACID DELIVERY | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel (DE) | 2025-10-22 | — | — | EP | claimed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | claimed |
| WO-2024173715-A1 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-22 | — | — | WO | claimed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20240167036-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | LONZA SALES AG (CH) | 2024-05-23 | — | — | US | claimed |
| WO-2024064729-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-28 | — | — | WO | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| US-20230218726-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | OKOGEN, INC. | 2023-07-13 | — | — | US | claimed |
| CN-115996715-A | Treatment of viral conjunctivitis | 奥可金公司 | 2023-04-21 | — | — | CN | claimed |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD. (AU) | 2010-11-18 | — | — | US | claimed |
| US-7825145-B2 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2010-11-02 | — | — | US | claimed |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | BIODIEM LTD. (AU) | 2009-01-08 | — | — | US | claimed |
| EP-1404665-A4 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2007-06-27 | — | — | EP | claimed |
| US-20060100258-A1 | Growth promotion method | BIODIEM LTD. (AU) | 2006-05-11 | — | — | US | claimed |
| EP-1597236-A1 | GROWTH PROMOTION METHOD | Biodiem Ltd. (AU) | 2005-11-23 | — | — | EP | claimed |
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | BIODIEM LTD (AU) | 2004-12-30 | — | — | US | claimed |
| WO-2004076423-A1 | GROWTH PROMOTION METHOD | BIODIEM LTD (AU) | 2004-09-10 | — | — | WO | claimed |
| EP-1404665-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | Biodiem Ltd. (AU) | 2004-04-07 | — | — | EP | claimed |
| WO-2002102789-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | BIODIEM LTD (AU) | 2002-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266844-A1 | Antimicrobial and radioprotective compounds | VIP, XPA, ERCC4 | NPC1 527/4885MTOR 1674/4885RAB9A 958/4885 |
| US-20100292317-A1 | ANTIMICROBIAL AND RADIOPROTECTIVE COMPOUNDS | RAD51, BRCA1, XPA | NPC1 1591/4885MTOR 2604/4885RAB9A 451/4885 |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | SYK, BTK, FYN | NPC1 2179/4885MTOR 1289/4885RAB9A 1945/4885 |
| US-20240167036-A1 | EXTRACELLULAR VESICLE-NLRP3 ANTAGONIST | NLRP3, MTREX, NLRP1 | NPC1 294/4885MTOR 3209/4885RAB9A 4037/4885 |
| US-20090012137-A1 | administering microbiocides such as 3,4-methylenedioxy- beta -nitrostyrene, for the treatment of urogenital disorders caused by Candida, Neisseria, Chlamydia or Trichomonas; side effect reduction of radiotherapy | TUBB1, UGT1A1, CYP1A1 | NPC1 695/4885MTOR 3796/4885RAB9A 1109/4885 |
| US-20060100258-A1 | Growth promotion method | HDGF, MKI67, GHRHR | NPC1 3101/4885MTOR 617/4885RAB9A 2147/4885 |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | NPC1 469/4885MTOR 3721/4885RAB9A 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.